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Garcı́a4☯, Juan Berenguer9☯, Arkaitz Imaz3☯, GESIDA-8314 Study Group¶
1 Hospital Universitario Infanta Leonor, Madrid, Spain, 2 Hospital Universitario Vall d’Hebrón, Barcelona,
Spain, 3 Hospital Universitario de Bellvitge, Barcelona, Spain, 4 Hospital Universitario La Paz/IdiPAZ,
Madrid, Spain, 5 Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, 6 Hospital General Universitario
de Alicante, Alicante, Spain, 7 Hospital Universitario Ramón y Cajal, Madrid, Spain, 8 Hospital de Mataró,
Mataró, Spain, 9 Hospital Regional Universitario de Málaga, Málaga, Spain, 10 Hospital Universitario
Gregorio Marañón, Madrid, Spain, 11 Hospital Clı́nico de Valencia, Valencia, Spain, 12 Hospital
Universitario Infanta Elena, Huelva, Spain, 13 Hospital del Mar, Barcelona, Spain, 14 Fundación SEIMC-
GESIDA, Madrid, Spain
☯ These authors contributed equally to this work.




Based on data from clinical practice, we evaluated the effectiveness and safety of switching
to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically sup-
pressed HIV-1-infected patients.
Methods
We performed a multicenter, non-controlled, retrospective study of HIV-1-infected patients
who switched treatment to ABC/3TC+RPV. Patients had an HIV-RNA <50 copies/mL for at
least 24 weeks prior to changing treatments. The primary objective was HIV-1 RNA <50
copies/mL at week 48. Effectiveness was analyzed by intention-to-treat (ITT), missing =
failure and on-treatment (OT) analyses. The secondary objectives analyzed were adverse
effects changes in renal, hepatic or lipid profiles, changes in CD4+ cell count and treatment
discontinuations.
Results
Of the 205 patients included, 75.6% were men and the median age was 49. At baseline,
before switching to ABC/3TC+RPV, median time since HIV diagnosis was 13.1 years,
median time with undetectable HIV-1 RNA was 6.2 years and median time of previous
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antiretroviral regimen was 3.1 years (48.3% patients were taking efavirenz and ABC/3TC
was the most frequent backbone coformulation in 69.7% of patients). The main reasons for
switching were drug toxicity/poor tolerability (60.5%) and simplification (20%). At week 48,
the primary objective was achieved by 187 out of 205 (91.2%) patients by ITT analysis, and
187 out of 192 (97.4%) patients by OT analysis. The CD4+ lymphocyte count and CD4+
percentage increased significantly from baseline to week 48 by a median of 48 cells/μL
(−50 to 189) and 1.2% (−1.3% to 4.1%), respectively, P<0.001. Thirty-eight adverse events
(AE) were detected in 32 patients. Of these, 25 had no clear association with treatment.
Three patients interrupted therapy due to AE. We observed a decrease in all lipid parame-
ters, P<0.001, and a slight improvement in the glomerular filtration rate, P<0.01. Therapy
was considered to have failed in 18 patients owing to virological failure (5 [2.4%]), toxicity/
poor tolerability (4 [2%]), clinical decision (3 [1.5%]), loss to follow-up (3 [1.5%]), death (1
[0.5%]), and no clinical data (2 [1%]).
Conclusions
The results of this study confirms that ABC/3TC+RPV is an effective, safe, and cost-effec-
tive option for the treatment of patients with virologically stable HIV-1 infection.
Introduction
First-line combined antiretroviral therapies (cART) are currently highly effective [1–2]. How-
ever, toxicity in the short and long term still arises as a main concern for clinicians managing
HIV infection.
Therapy regimens are sometimes switched to improve or maintain the patient’s quality of
life and, in a few cases, to reduce treatment costs [3]. Strategies used when switching cART reg-
imens are aimed at improving a patient’s quality of life without compromising treatment effec-
tiveness. This is accomplished through the discontinuation of toxic drugs, the identification of
poorly tolerated drugs and the management of drug interactions [4–6].
The combination of abacavir/lamivudine (ABC/3TC) is widely used in both clinical trials
and real-world practice, especially when clinicians wish to avoid the toxicity of older nucleo-
side/nucleotide analogues, such as zidovudine, didanosine, stavudine and tenofovir (TDF)
[7–9].
Based on the ECHO and THRIVE clinical trials [10–14] the second-generation non-nucleo-
side reverse-transcriptase inhibitor (NNRTI) rilpivirine (RPV) has been approved for treat-
ment-naïve HIV-1-infected patients. Information about its combination with ABC/3TC in
clinical trials is scarce, although favorable efficacy and safety results were observed in a small
group of 35 treatment-naïve patients in the THRIVE clinical trial [12]. Clinical studies with
RPV as a switching strategy have only been performed in combination with tenofovir/emtrici-
tabine (TDF/FTC), demonstrating high efficacy, good tolerability profiles and high adherence
[15–18].
The combination ABC/3TC+RPVmight simultaneously address the issues of effectiveness,
tolerability and ease of administration as an alternate therapy in routine clinical practice.
Given the lack of evidence on switching to ABC/3TC+RPV, it is important to test the feasi-
bility of this strategy. We carried out a study to explore the effectiveness and safety of switching
to a regimen comprised of a fixed-doseABC/3TC and RPV in virologically suppressed HIV-
1-infected patients.
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Methods
Study design and patients
This was a multicenter, non-controlled and retrospective study of HIV-1-infected patients
switching to ABC/3TC+RPVconducted in 13 hospitals in Spain. All included patients had to
fulfill the following criteria: i) age18 years, ii) documentedHIV-1 infection, iii) switch from
another therapy regimen to coformulated ABC/3TC (600/300 mg fixed-dose combination)
and RPV (25 mg) once daily for any reason from March 2013 to March 2014 and iv) serum
HIV RNA <50 copies/mL for at least 24 weeks before switching to ABC/3TC+RPV. Analysis
was carried out in 2015, to ensure that the final patient included in 2014 had at least 48 weeks
of follow up. Patients tested negative for HLAB5701 before initiating ABC/3TC+RPV.
Eligible individuals were identified by a systematic search of the databases of each center.
Data for the study was collected retrospectively from patient´s medical records, anonymized
and entered into an electronic database. The information collected included: baseline demo-
graphic and HIV-related data, comorbidities, adverse events and laboratory results (blood
count, biochemical parameters including lipid profile and liver and kidney function, CD4
+ lymphocyte count, and HIV RNA), at baseline and thereafter according to the routine clinical
protocols in each hospital (every 12 to 24 weeks), reasons for treatment discontinuation in
patients who stopped or changed therapy, and results of genotypic resistance testing after viro-
logical failure, when available.
The study protocol was approved by the Hospital Universitario Gregorio Marañón Ethics
Committee with code SEI-RIL-2014-02, in accordance with the principles of the Declaration of
Helsinki 2008. The study required local approval of several other Clinical Research Ethics
Committees: Hospital Universitario Vall d´Hebrón Ethics Committee, Hospital de Mataró-
Consorcio Sanitario del Maresme Ethics Committee, Hospital Universitario de Bellvitge Ethics
Committee, Hospital Clínico Universitario de Valencia Ethics Committee and Ethics Commit-
tee of the province of Huelva.
Analysis with a view to scientific publication was based on anonymized routine clinical
data, thus obviating the need for written informed consent.
Outcomes
The primary objective was the percentage of patients who maintained virological suppression
(HIV-1 RNA <50 copies/mL) after 48 weeks of treatment. This outcome was analyzed using
intention to treat (ITT),missing = failure and on treatment (OT) analyses. Treatment was con-
sidered to have failed when any of the following events occurred: virological failure (VF),
defined as two consecutive HIV RNA measurements>50 copies/mL or a single measurement
of>50 copies/mL if treatment was changed afterwards; treatment interruption by patient;
change of treatment regimen due to non-VF reasons and incomplete data. Viral load was eval-
uated 3 or 4 times during the 48-week period of the study to ascertain virologic control, accord-
ing to the routine clinical protocols in each hospital. The secondary objectives were adverse
events, changes in CD4 count, lipid, hepatic or renal profile changes, treatment discontinua-
tions and reasons for discontinuations.
Statistical analysis
All analyses were carried out using IBM SPSS Statistics for Windows1, Version 21.0 (SPSS,
Chicago, IL, USA).
We analyzed the variables available at baseline and at 48 weeks. Variables that did not follow
a normal distribution were describedusing the median and interquartile range (IQR). Nominal
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variables were described as numbers and percentages. Paired samples were compared using the
t test (normally distributed variables) and the Wilcoxon test (non-normally distributed vari-
ables). Normality of the variables was tested with the Kolmogorov-Smirnov-Lilliefords test.
The association between qualitative variables was assessed using the χ2 test when the sample
was sufficiently large or Fisher's exact test when it was not. The 95% confidence intervals were
calculated based on the Newcombe-Wilson hybrid score.
For the primary outcome (ITT analysis), we included all registered patients (incomplete or
missing patients were defined as failures). We also performed an analysis excluding patients
whose treatment was discontinued for non-virological reasons (OT analysis).
Results
The study population comprised 205 patients. Baseline patient characteristics are summarized
in Table 1. Men accounted for 76% of the sample, median age was 49 years, a quarter of
patients had prior AIDS-defining conditions, and a fifth were co-infectedwith hepatitis C virus
(HCV). At baseline, median CD4+ lymphocyte count was 667 cells/μL, and the median CD4+
lymphocyte nadir was 198 cells/μL.
At baseline, before switching to ABC/3TC+RPV, median time from HIV diagnosis was 13.1
years, median time from first antiretroviral treatment was 9.6 years, median time of previous antire-
troviral regimenwas 3.1 years and median time with undetectableHIV-1 RNA was 6.2 years.
Prior to switching, 63 patients (30.7%) were taking a ritonavir-boosted protease inhibitor
(bPI) and 122 patients (59.4%) a NNRTI (efavirenz, EFV, 48.3%). TDF was part of the previous
backbone in 53 patients (25.8%) and ABC in 144 (70.2%). Of note, ABC/3TC was the most fre-
quent nucleoside reverse transcriptase inhibitor (NRTI) backbone coformulation before
switching (69.7%). The main reasons for switching were drug toxicity/tolerability in 124 cases
(60.5%) and regimen simplification in 41 (20%). In the toxicity/tolerability group of patients,
82 (65.3%) were on EFV-based regimens and 25 (20.2%) on bPI-based regimens. Regimen sim-
plification (doses per day or number of pills) resulted primarily from bPI and etravirine-based
regimens (51.2% and 22%, respectively).
The primary objective was observed in 187 out of 205 patients (91.2% [95% CI, 86.5–94.7])
by ITT analysis. When patients who had discontinued therapy for non-virological reasons
were excluded, 187 out of 192 patients (97.4% [95% CI, 94–99.1]) reached the primary outcome
per protocol (OT analysis) (Fig 1). Therapy failed in 18 patients (8.8%), including 15 who dis-
continued ABC/3TC+RPV. The reasons for discontinuation were toxicity/poor tolerability (4
[2%]), virological failure (2 [1%]), physician’s decision (3 [1.5%]), loss of clinical patient moni-
toring or patient’s decision (3 [1.5%]), death (1 [0.5%]), and no clinical data at the evaluation
time point (2 [1%]). At week 48, five patients (2.4%) experiencedprotocol-defined virological
failure. Of these, two continued with ABC/3TC+RPVafter two consecutive low-level detectable
HIV-1 RNA determinations (at weeks 6 and 24), and both had undetectableHIV-1 RNA at
week 48. The other three patients had detectable HIV-1 RNA during the study period (two
patients betweenweeks 4 and 8, and one patient at week 48). All three patients underwent
resistance testing at the time of virological failure. Genotyping could not be performed in one
patient due to an HIV-1 RNA level below 200 copies/mL, and in the other two patients, the
resistance mutations found were as follows: NRTI mutations (M41L, M184V, T215F, K219Q)
and NNRTI mutations (A98G, K103N, K238T) in one patient; and NRTI mutations (A62V,
M184V), a NNRTI mutation (E138K), and a bPI mutation (L33V) in the other patient. Before
switching to ABC/3TC+RPV, the available genotypic resistance tests did not show resistance
mutations that would have compromised this treatment strategy. Therefore, no patients were
excluded from the study for previous resistance mutations.
Switching Strategy with ABC/3TC plus Rilpivirine
PLOS ONE | DOI:10.1371/journal.pone.0164455 October 11, 2016 4 / 12
Table 1. Baseline characteristics of the study patients.
(n = 205)




HIV risk factors; n (%)
Sexual relations between MSM 62 (30.2)
Heterosexual relations 65 (31.7)
IDU 61 (29.7)
Other/Unknown 17 (8.3)
Baseline CD4; median (IQR)
CD4 count (cells/μ) 667 (471–870)
CD4% 31 (23–38)
Nadir CD4 (cells/μ); median (IQR) 198 (87–288)
AIDS diagnosis; n (%) 54 (26.3)
Time since HIV diagnosis (years); median (IQR) 13.1 (6.1–18.7)
Months since undetectable viral load (<50 copies/mL); median (IQR) 74.8 (35.8–117.0)
Comorbidities; n (%)
HBV (HbsAg +) 4 (2)
HCV (PCR +) 41 (20)
Hypertension 44 (22.5)
Diabetes mellitus 19 (9.3)
Dyslipidemia 59 (28.8)
Ischemic heart disease 12 (5.9)
Kidney disease 10 (4.9)
Reasons for switching; n (%)
Drug toxicity/tolerability 124 (60.5%)
Regimen simplification 41 (20%)
Physician’s criteria* 23 (11.2%)
Cost savings 3 (1.5%)
Unknown reasons 14 (6.8%)







Darunavir (monotherapy: 2) 22 (10.7)
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The median CD4+ lymphocyte count and median CD4+ percentage increased significantly
from baseline to week 48 by a median of 48 cells/μL (−50 to 189) and 1.2% (-1.3% to 4.1%),




MSM: men who have sex with men; IDU: injection drug user; AIDS: acquired immunodeficiency syndrome;
HBV: hepatitis B virus; HCV: hepatitis C virus; cART: combined antiretroviral treatment.
* Potential drug interactions, better profile, a personal decision.
doi:10.1371/journal.pone.0164455.t001
Fig 1. Study Flowchart. * ITT analysis: including all registered patients (incomplete or missing patients were
included with patients whose treatment had failed). **OT analysis: excluding patients who discontinued treatment
for non virological reasons. VF: virological failure, VL: viral load, cART: combined antiretroviral treatments.
doi:10.1371/journal.pone.0164455.g001
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lymphocyte count and CD4+ percentage also increased significantly by a median of 50 cells/μL
(−19 to 182.5) and 1.7% (−0.5% to 4.3%), respectively, P<0.001.
In this study cohort, 38 adverse events (AEs) were registered among 32 patients (15.6%)
(Table 2). Clinical intervention was unnecessary for 33 of the events, and 25 resolved. Medica-
tion was discontinued in three (1.5%) of the five patients who required clinical intervention.
The reasons for discontinuation were insomnia/depression, dizziness, and epigastralgia. Severe
AEs were not related to medication, but moderate AEs could have been associated to the treat-
ment in 3 patients. In 25 events, clinicians did not find a clear correlation between the event
and antiretroviral therapy.
Median changes in lipid, hepatic, and renal profiles were analyzed at week 48 (Table 3). In
this cohort of patients a small but statistically significant decrease in lipid levels were observed:
total cholesterol (T-chol), with a percent change of −9.1% (median change, IQR, −18 [−47 to 3]
mg/dL); low-density lipoprotein cholesterol (LDL-chol), −8.9% (−10.8 mg/dL [−43 to 9 mg/
dL]); high-density lipoprotein cholesterol (HDL-chol), −7% (−4 mg/dL [−9 to 1 mg/dL]) and
triglycerides (TG), −15% (−19 mg/dL [−51 to 12 mg/dL]); P<0.001 for all differences. There
was no significant difference in lipid profiles in patients previously on a bPI-based regimen,
but patients previously on an EFV-based regimen presented changes in T-chol, −15.4% (−29.6
mg/dL [−55.5 to −9 mg/dL], P<0.01), LDL-chol -14.6% (−20.5 mg/dL [−47 to 1.6 mg/dL],
P<0.01), HDL-chol, −9.8% (−5 mg/dL [−9 to 0 mg/dL], P<0.01) and TG −20.3% (−28 mg/dL
[−55 to 1.2 mg/dL], P<0.01).
Table 2. Overview of adverse events (AEs).
Summary of AE
Patients with 1 AE 32
Total number of AE 38
Patients with1 Grade 3–4 AE 4
Total number of Grade 3 or 4 AE 5
Patients with serious AE 1
Total number of serious AE 1









Severity of adverse events
Severe (fatal or life-threatening) 1
Moderate (requires medical treatment or hospitalization) 5
Mild (symptoms do not require major medical intervention) 32






* Insomnia/depression, dizziness, epigastralgia.
doi:10.1371/journal.pone.0164455.t002
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Table 3. Laboratory values at baseline and at week 48.*
LIPID PROFILE N Median P. 25 P. 75 p
Total cholesterol Baseline (mg/dL) 192 202.9 178.0 233.1
At week 48 (mg/dL) 179 186.0 158.0 209.0
Change 167 −18.0 −47.0 3.0 <0.001$
Percentage change 167 −9.1 −22.1 1.6
High-density lipoprotein cholesterol Baseline (mg/dL) 151 49.0 40.2 62.0
At week 48 (mg/dL) 152 46.0 39.0 58.0
Change 123 −4.0 −9.0 1.0 <0.001¥
Percentage change 123 −7.0 −17.1 2.0
Low-density lipoprotein cholesterol Baseline (mg/dL) 144 123.7 93.5 153.5
At week 48 (mg/dL) 146 113.8 91.0 135.0
Change 118 −10.8 −43.0 9.0 <0.001$
Percentage change 118 −8.9 −27.1 10.7
Triglycerides Baseline (mg/dL) 190 134.5 84 204
At week 48 (mg/dL) 180 108.0 75.5 163.5
Change 167 −19.0 −51.0 12.0 <0.001¥
Percentage change 167 −15.0 −33.5 12.3
LIVER PROFILE
Aspartate aminotransferase Baseline (IU/L) 164 25.0 20.0 34.0
At week 48 (IU/L) 155 24.0 20.0 31.0
Change 140 0.5 −4.0 4.0 0.953¥
Alanine aminotransferase Baseline (IU/L) 189 25.8 17.0 40.0
At week 48 (IU/L) 181 25.0 18.0 40.0
Change 167 1.0 −9.0 8.0 0.931¥
Gamma-glutamyl transpeptidase Baseline (IU/L) 167 39.0 23.0 71.4
At week 48 (IU/L) 165 29.0 21.0 53.0
Change 143 −7.0 −26.0 2.0 <0.001¥
Alkaline phosphatase Baseline (IU/L) 177 87.0 68.0 108.0
At week 48 (IU/L) 151 75.0 62.0 90.0
Change 145 −12.0 −29.0 -1.0 <0.001¥
Bilirubin Baseline (mg/dL) 154 0.5 0.4 0.70
At week 48 (mg/dL) 139 0.5 0.4 0.6
Change 122 0.0 −0.1 0.1 0.812¥
RENAL PROFILE
Estimated glomerular filtration rate Baseline 127 82.0 71.0 97.0
At week 48 147 89.4 74.6 99.6
Change 107 1.1 −4.8 10.0 <0.01¥
CD4+ LYMPHOCYTE COUNT
Baseline (cells/μL) 197 667 471 870
Absolute CD4 At week 48 (cells/μL) 174 741 505 942
Change 167 48 −50 189 <0.001¥
Baseline 199 31.0 23.7 38.0
% CD4 At week 48 175 34.0 27.0 38.8
Change 170 1.2 −1.3 4.1 <0.001¥
* Taking into account the retrospective nature of the study and according to the different routine clinical protocols in each hospital not all the patients had a
baseline or 48-week lipid, hepatic or renal profiles.
$ p value Paired Samples T-test (parametric variables).
¥ p value Wilcoxon Signed-Rank test (nonparametric variables).
doi:10.1371/journal.pone.0164455.t003
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No changes were observed in liver profiles (aspartate aminotransferase, alanine aminotrans-
ferase, and bilirubin) at week 48, except for a slight decrease in gamma-glutamyl transpeptidase
and alkaline phosphatase levels. This decrease was especially significant in the group of patients
previously on an EFV-based regimen, median gamma-glutamyl transpeptidase of −18.5 IU/L
(−41.7 to −7 IU/L) and a median alkaline phosphatase of −16.4 IU/L (−35 to −5 IU/L), P<0.01.
The estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease equa-
tion) increased by a median (IQR) of 1.1 mL/min/1.73m2 (−4.8 to 10) by week 48, P<0.01.
Most of the patients who attained an increase in eGFR were taking TDF before switching
(n = 55) and these patients had a median increase in eGFR of 7 mL/min/1.73m2 (−5.8 to 13.1)
at the end of follow-up, P<0.04. There were no significant changes in eGFR in patients previ-
ously on EFV or bIP-based regimens.
Discussion
To our knowledge, there is little data showing that switching to ABC/3TC+RPV is effective,
safe, and well tolerated in virologically suppressed HIV-1-infected patients. Previous studies
have demonstrated that when switched from EFV+FTC/TDF, RPV+FTC/TDF is not inferior
in terms of efficacy, has a better tolerability profile (resolving neuropsychiatric toxicity), and
patients have a high adherence to this regimen [17, 18]. In terms of effectiveness, our findings
also revealed a high virological suppression rate (above 90% at 48 weeks of follow-up), which
in fact is similar to other reported studies on treatment switching [15–20].
Of the 205 patients included, 18 experienced treatment failure, although only five experi-
enced protocol-defined virological failure during the 48 weeks of the study period. Interest-
ingly, two of those patients presenting as virological failures had two consecutiveHIV-1 RNA
values between 50 and 200 copies/mL and later achieved and maintained HIV-1 RNA <50
copies/mL without having to modify their treatment. Resistance testing performed on samples
from the other three patients who experiencedvirological failure revealed mutations that may
have compromised the efficacy of the regimen in two cases. A high proportion of patients
maintained an undetectable viral load at week 48 after the switch, probably because of the
excellent tolerability profile of ABC/3TC+RPVand the good adherence motivated by the low
pill burden and once-daily regimen.
We documented a median increase of 48 cells/μL (7.2%) in the CD4+ lymphocyte count but
only a 1.2% increase in the percentage of CD4+ cells. Immune function was largely unchanged
given the small and clinically insignificant change in CD4%. The absolute CD4 change may
have been driven by increases in white blood cells or total lymphocyte count. Further follow-
up would be needed in order to observe potential clinically significant changes.
The frequency of adverse events was low (15.6%). The attending physicians considered
most events to be unrelated to the study medication, and most AES resolved. Only three
patients discontinued the regimen owing to adverse events. The low number of discontinua-
tions due to poor tolerability indicates that the regimen was well tolerated.
A small irrelevant decrease was observed in the serum concentrations of all fasting lipids.
This observationwas more evident in the group of patients with a previous EFV-based regi-
men, comprising nearly half of the patients who switched to RPV+ABC/3TC.This finding is
similar to findings described in other studies with EFV, in naïve or treated patients [21, 22]. No
significant changes were observed in the subgroup of previous bPI-based regimens despite
findings in other studies [23].
Additionally, serumbiochemistry analysis revealed a small but statistically significant
decrease in alkaline phosphatase and gamma-glutamyl transpeptidase levels, especially among
the group of patients with a previous EFV-based regimen. EFV is known to produce enzyme
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induction in the liver through CYP3A4 and has been described in the EFV data sheet in 7% of
the patients who receive 600 mg of this drug [24].
Despite a significant median increase in eGFR of 1.1 mL/min/1.73m2, no clinical relevance
could be established. This increase is much more striking in the subgroup of patients who
switched to ABC/3TC+RPV from a regimen containing TDF with a median increase in the
eGFR of 7 mL/min/1.73m2. This finding may reflect either a decrease in the inhibition of the
tubular secretion of creatinine or an improvement in renal function after removing TDF from
the regimen [25, 26]. Future availability of tenofovir-alafenamide (TAF) resulting in a better
renal profile could avoid the potential renal damage observed in some patients using TDF [27].
Our study has several limitations. First, it was a retrospective study. Second, there were dif-
ferences in clinical protocols and visit timetables between the study centers. It also lacked a
comparative arm.
Nevertheless, our findings are relevant, because ABC/3TC+RPVproved to be highly effec-
tive in virologically suppressed HIV-1-infected patients. Therefore, this combination could
potentially form the basis for a switching strategy, especially when TDF cannot be taken
because of toxicity issues, resistance, or clinical reasons. Safety is yet another key advantage of
ABC/3TC+RPV. For example, adverse events are infrequent and a regimen free of TDF has
potential long-term benefits for the kidneys and bones.
In addition, this switching strategy could be cheaper than the most common antiretroviral
regimens that include protease and integrase inhibitors. These savings can have a significant
economic impact on the hospital drug expenses.
In summary, the results of the SIMRIKI study support the use of ABC/3TC+RPVas an
effective, safe, well-tolerated and cost-effective switching strategy in patients with virologically
stable HIV-1 infection.
Acknowledgments
We thank the SIMRIKI study patients and all investigators and Institutions of GESIDA-8314
study group. We also thank Cristina Jiménez and Xolimar Pereiro (ViiV Healthcare Medical
Scientific Liaison) for their continued support. Data presented at the 15th European AIDS Con-
ference, Barcelona (21–24 October 2015).
Contributors
Members of the GESIDA-8314 Study Group are: J. Troya, P. Ryan, G. Cuevas, J. Solís. Hos-
pital Universitario Infanta Leonor, Madrid, Spain); E. Ribera. Hospital Universitario Vall
d’Hebrón, Barcelona, Spain; D. Podzamczer, A. Imaz, L. Acerete. Hospital Universitario de
Bellvitge, Barcelona, Spain; J. González-García, V. Hontañón. Hospital Universitario La Paz,
Madrid, Spain; J.A. Terrón. Hospital Jerez de la Frontera, Jerez de la Frontera, Spain; V. Boix, J.
Portilla, E. Merino, S. Reus, D. Torrús, L. Giner, I. Portilla, M. Pampliega, M. Díez. Hospital
General Universitario de Alicante, Alicante, Spain; S. Moreno, MJ. Pérez, A. Díaz, J.L. Casado,
A. Moreno, F. Dronda, C. Gómez, S. Serrano Hospital Universitario Ramón y Cajal, Madrid,
Spain; P. Barrufet, L Force. Hospital de Mataró, Mataró, Spain; M. Castaño, M.I. Mayorga, F.
Orihuela, F. Jiménez. Hospital Carlos Haya, Málaga, Spain; J. Berenguer, A. Carrero. Hospital
Universitario Gregorio Marañón, Madrid, Spain; J. Galindo. Hospital Clínico de Valencia,
Valencia, Spain; I. Suárez-Lozano, M. Raffo, M.D. Merino, F. Rodriguez, J.M. Fajardo, F.J. Mar-
tínez, A. Hidalgo-Castejón; S. de la Rosa. Hospital Universitario Infanta Elena, Huelva, Spain;
H. Knobel. Hospital del Mar, Barcelona, Spain; H. Esteban, M. Yllescas. Fundación SEIMC-
GESIDA, Madrid, Spain.
 Lead author for this group: Jesús Troya García (email: jestrogar@hotmail.com)
Switching Strategy with ABC/3TC plus Rilpivirine





Investigation: JT PR ER DP VH JAT VB SM PB MC AC MJG IS HK MR JS JG JB AI.
Methodology: JT PR.
Project administration:MY HE GESIDA.
Resources: JT PR ER DP VH JAT VB SM PB MC AC MJG IS HK MR JS JG JB AI.
Supervision: JT PR.
Visualization: JT PR.
Writing – original draft: JT PR.
Writing – review& editing: JT PR JB JG AI.
References
1. European Guidelines for treatment of HIV-infected adults in Europe. Guidelines version 8.0. European
AIDS Clinical Society (EACS), October, 2015. Available: http://www.eacsociety.org/files/2015_
eacsguidelines_8.0-english_revised-20151104.pdf. Accessed 2015 Nov 9.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral
Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services USA,
January 28, 2016. Available: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.
pdf. Accessed 2016 Feb 11.
3. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract.
2007; 61 (Suppl 6): S999–S1014. doi: 10.1111/j.1742-1241.2007.01385.x PMID: 17504362
4. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE. Treatment simplification in HIV-infected
adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare
costs. Patient Prefer Adherence. 2011; 5: 357–367. doi: 10.2147/PPA.S22771 PMID: 21845035
5. Ford N, Flexner C, Vella S, Ripin D, Vitoria M. Optimization and simplification of antiretroviral therapy
for adults and children. CurrOpin HIV AIDS. 2013; 8 (Suppl 6): S591–S599. doi: 10.1097/COH.
0000000000000010 PMID: 24100871
6. Casado JL, Moreno S. Potential role of rilpivirine in simplification regimens. Enferm Infecc Microbiol
Clin. 2013; 31 (Suppl 2): S30–S35. doi: 10.1016/S0213-005X(13)70140-X PMID: 24252531
7. Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, et al. Comparison of bone
and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a random-
ized trial. Plos One. 2012; 7 (Suppl 3): e32445. doi: 10.1371/journal.pone.0032445 PMID: 22479327
8. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of
changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-
infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010; 51: 963–972. doi: 10.
1086/656417 PMID: 20828304
9. Moyle GJ, Stellbrink HJ, Orkin C, Arribas JR, Domingo P, Granier C, et al. 96-week results of abacavir/
lamivudine versus tenofovir/emtricitabine, plus efavirenz in antiretroviral-naive, HIV-1 infected adults:
ASSERT study. Antivir Ther. 2013; 18 (Suppl 7): S905–S913. doi: 10.3851/IMP2667 PMID: 23899468
10. Edurant®. Data Sheet. European Medicines Agency. Available: http://www.ema.europa.eu/docs/es_
ES/document_library/EPAR_-_Product_Information /human/002264/WC500118874.pdf. Accessed
2016 Jul 12.
11. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with
tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 rando-
mised double-blind active-controlled trial. Lancet. 2011; 378: 238–246. doi: 10.1016/S0140-6736(11)
60936-7 PMID: 21763936
Switching Strategy with ABC/3TC plus Rilpivirine
PLOS ONE | DOI:10.1371/journal.pone.0164455 October 11, 2016 11 / 12
12. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine
versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treat-
ment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet.
2011; 378: 229–237. doi: 10.1016/S0140-6736(11)60983-5 PMID: 21763935
13. Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, et al. Rilpivirine versus efavirenz
in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and
THRIVE Studies. HIV Clin Trials. 2013; 14 (Suppl 3): S81–S91. doi: 10.1310/hct1403-81 PMID:
23835510
14. Putcharoen O, Kerr SJ, Ruxrungtham K. An update on clinical utility of rilpivirine in the management of
HIV infection in treatment-naïve patients. HIV AIDS. 2013; 16 (Suppl 5): S231–S241. doi: 10.2147/
HIV.S25712 PMID: 24068877
15. Ward D, Grant R. Rilpivirine/tenofovir/emtricitabine fixed-dose combination is an efficacious and well-
tolerated “switch” regimen for patients on therapy. J Int AIDS Soc. 2012; 15 (Suppl 4): S18351. doi: 10.
7448/ias.15.6.18351
16. Cevik M, Sonecha S, Nelson M. Safety and efficacy of fixed-dose combination rilpivirine-tenofovir-
emtricitabine (RPV/TDF/FTC) in treatment-experienced patients infected with HIV-1. J Int AIDS Soc.
2012; 15 (Suppl 4): S18291. doi: 10.7448/ias.15.6.18291
17. Mills AM, Cohen C, Dejesus E, Brinson C, Williams S, Yale KL, et al. Efficacy and safety 48 weeks
after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based sin-
gle-tablet regimens. HIV Clin Trials. 2013 Sep-Oct; 14(5):216–223 doi: 10.1310/hct1405-216 PMID:
24144898
18. Cazanave C, Reigadas S, Mazubert C, Bellecave P, Hessamfar M, Le Marec F, et al. Switch to Rilpivir-
ine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Sup-
pressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3
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